SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria and Other Mast Cell-Mediated Diseases - Septerna

06.14.25

Publication

Up Next

View All

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

No results found.